Skip to main content
Top

Cancer Chemotherapy and Pharmacology

Issue 2/2006

Content (17 Articles)

Original Article

Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex

David J. Adams, Mateus Webba da Silva, James L. Flowers, Glenda Kohlhagen, Yves Pommier, O. Michael. Colvin, Govindarajan Manikumar, Mansukh C. Wani

Original Article

Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient

David J. Adams, Miriam L. Wahl, James L. Flowers, Banalata Sen, Michael Colvin, Mark W. Dewhirst, Govindarajan Manikumar, Mansukh C. Wani

Original Article

Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies

Sarah A. Holstein, Howard R. Knapp, Gerald H. Clamon, Daryl J. Murry, Raymond J. Hohl

Original Article

4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells

Hideaki Nakazawa, Shuichi Yoshihara, Daisuke Kudo, Hajime Morohashi, Ikuko Kakizaki, Atsushi Kon, Keiichi Takagaki, Mutsuo Sasaki

Original Article

Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells

Olaf H. Temmink, Marco F. M. Hoogeland, Masakazu Fukushima, Godefridus J. Peters

Original Article

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

Vittorio Ferrari, Francesca Valcamonico, Vito Amoroso, Edda Simoncini, Lucia Vassalli, Patrizia Marpicati, Giovanni Rangoni, Salvatore Grisanti, Guido AM Tiberio, Franco Nodari, Carla Strina, Giovanni Marini

Original Article

Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study

Cheri E. Klein, Helen Kastrissios, Antonius A. Miller, Donna Hollis, Daohai Yu, Gary L. Rosner, David L. Grinblatt, Richard A. Larson, Mark J. Ratain

Original Article

Combination of topotecan and cisplatin in relapsed patients with small cell lung cancer: a phase II study of the hellenic cooperative oncology group (HeCOG)

Christos Christodoulou, Haralambos P. Kalofonos, Evangelos Briasoulis, Dimitrios Bafaloukos, Thomas Makatsoris, Angelos Koutras, Dimosthenis V. Skarlos, Epaminondas Samantas

Original Article

Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II

Brian B. Hasinoff, Xing Wu, Asher Begleiter, Lynn J. Guziec, Frank Guziec Jr, Angela Giorgianni, Shaohua Yang, Yu Jiang, Jack C. Yalowich

Original Article

Expression of VDR and CYP24A1 mRNA in human tumors

Mark G. Anderson, Masaki Nakane, Xiaoan Ruan, Paul E. Kroeger, J. Ruth Wu-Wong

Original Article

Prospective evaluation of carboplatin AUC dosing in patients with a BMI ≥27 or Cachexia

Jon D. Herrington, Hai T. Tran, Mark W. Riggs

Original Article

Experimental study of the inhibition of human hepatocarcinoma Bel7402 cells by the tripeptide tyroserleutide(YSL)

Rong Lu, Jing Jia, Leyuan Bao, Zheng Fu, Guoli Li, Song Wang, Zhuo Wang, Mengjue Jin, Wenyuan Gao, Zhi Yao

Original Article

Analysis of cytotoxicities of platinum compounds

Jerry Goodisman, Douglas Hagrman, Kirk A. Tacka, Abdul-Kader Souid

Original Article

Antiproliferative activity of contragestazol (DL111-IT) in murine and human tumor models in vitro and in vivo

Bo Yang, Qiao-jun He, Dan-yan Zhu, Yi-jia Lou, Rui-ying Fang

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine